TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An update from Prophase Labs ( (PRPH) ) is now available.
On September 12, 2025, ProPhase Labs entered into a Strategic Advisory and Private Placement Agreement with ThinkEquity LLC to serve as its exclusive strategic advisor, placement agent, and investment banker. The agreement involves a proposed private placement of approximately $6 million in securities, with ThinkEquity receiving compensation in cash and warrants. This strategic move is part of ProPhase Labs’ digital asset treasury strategy, potentially impacting its operations and market positioning by involving significant crypto asset accumulation and board representation rights for ThinkEquity.
The most recent analyst rating on (PRPH) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on Prophase Labs stock, see the PRPH Stock Forecast page.
Spark’s Take on PRPH Stock
According to Spark, TipRanks’ AI Analyst, PRPH is a Neutral.
Prophase Labs’ overall stock score is primarily impacted by its financial challenges, including declining revenues and negative profitability. While technical indicators show some positive momentum, valuation concerns persist due to a negative P/E ratio. The earnings call and corporate events provide some optimism with potential cash recovery and strategic initiatives, but these are overshadowed by current financial instability.
To see Spark’s full report on PRPH stock, click here.
More about Prophase Labs
ProPhase Labs, Inc. operates in the healthcare industry, focusing on developing and marketing over-the-counter consumer healthcare products and dietary supplements.
Average Trading Volume: 6,136,449
Technical Sentiment Signal: Sell
Current Market Cap: $17.54M
See more insights into PRPH stock on TipRanks’ Stock Analysis page.